Pharmacyclics — Investor Presentation (July 2009)
38 slides from Pharmacyclics's investor presentation, Jul 24, 2009
Slide 1: Investor Presentation July 2009
Investor Presentation July 2009
Slide 2: Safe-Harbor Statement
Pharmacyclics, Inc. Safe-Harbor Statement During the course of this presentation we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or pot
Slide 3: Website and Contact Information
Pharmacyclics, Inc. To learn about each of our drugs, their development status and to get further explanations and definitions of technical terms please go to our website at: www.pharmacyclics.com. Contact Information: Ramses Erdtmann VP Finance 995 East Arques Avenue Sunnyvale, CA 94085 Tel: 408-77
Slide 4: The New Pharmacyclics: Investment Highlights
The New Pharmacyclics Investment Highlights § New direction, new management team and new board § Significant insider ownership § Four drugs in the clinic and three drugs in preclinical development § Oncology, autoimmune, allergy and asthma therapies § Programs are novel for validated molecular targe
Slide 5: The New Pharmacyclics: Investment Highlights
The New Pharmacyclics Investment Highlights § Partnered HDAC molecule for $39.5 million of which $15 million is guaranteed. § A high single-digit royalty is due based on sales. § Les Laboratoires Servier, the second largest French pharmaceutical company worldwide, also purchased HDAC product from Ph
Slide 6: Our Mission Statement
Our Mission Statement § To build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs. § To identify promising product candidates based on excepti
Slide 7: Risk Reduction with Four Clinical Programs
Risk Reduction with Four Clinical Programs § Oncology BTK Inhibitor - PCI - 32765 - Phase I § Potential oral therapy for B cell malignancies § Currently conducting Phase I, Phase II planned late 2009 § Autoimmune and mast cell clinical Proof of Concept Studies to begin first half of 2010 § Autoimmun
Slide 8: Pharmacyclics Development Portfolio
Pharmacyclics Development Portfolio A Full Pipeline with Near Term Milestones NAME INDICATION DESCRIPTION STATUS PCI-32765 B cell lymphoma Oral BTK Inhibitor for Phase I BCR expressing tumors Allergic and Oral BTK Inhibitor Phase I planned 1H 2010 Autoimmune B and mast cells Disorders PCI-4 Series A
Slide 9: Management Team
Management Team Experienced Leadership, Scientific Expertise & Large Mgmt Ownership Bob Duggan - CEO & Chairman § Highly successful entrepreneur; “Pioneer of Robotic Surgery”; over 30 million in equity invested § Significant value created in his career of starting and operating companies Glenn Rice,
Slide 10: Active and Distinguished Scientific & Clinical Advisory Board
Active and Distinguished Scientific & Clinical Advisory Board Daniel Von Hoff, MD (TGen Institute, Arizona) § Physician in Chief & Director; CSO of US Oncology, past AACR President Branimir I. Sikic, MD (Stanford University) § Co-Director, Stanford Center for Clinical and Translational Education and
Slide 11: Large Addressable Markets
Large Addressable Markets BTK Bruton’s Tyrosine Kinase >$8 Billion Market Partner ex-US Lymphoma, Autoimmune, Allergy & Asthma Factor VIIa HDAC Histone Deacetylase >$1 Billion Market >$700 Million Market Pancreatic and First in Class Solid Tumors GI Tumors First in Clinic Lymphomas Class Leading
Slide 12: BTK-Targeted Development Program
BTK-Targeted Development Program Two independent programs PCI-32765 – Oncology - Currently in Phase I B cell malignancies § First-in-man BTK Inhibitor, orally administered small molecule § Optimized for potency to achieve BTK inhibition at subnanomolar levels § Phase II non-Hodgkin’s lymphoma target
Slide 13: XLA Disease – Substantial Clinical Risk Reduction for Safety and Efficacy
XLA Disease – Substantial Clinical Risk Reduction for Safety and Efficacy § Mutations in BTK result in XLA (humans) and xid (mice) § Patients with XLA have no mature B cells and produce no immunoglobulin § T cell function is not affected § No abnormalities occur in any organs or tissues outside of t
Slide 14: Highly Specific Small Molecule B Cell Inhibitor Without T Cell Effect
Highly Specific Small Molecule B Cell Inhibitor Without T Cell Effect Wash Wash 1 hr 20 hrs 1 hr 20 hrs Activated B cell Add drug Stimulate T cell with Activated T cell Add drug Stimulate B cell with (CD69 +) anti-CD3/CD28 (CD69 +) anti-IgM 1 hour exposure 1 hour exposure 100% B cell - washout 120%
Slide 15: DMARD efficacy in collagen induced arthritis
DMARD efficacy in collagen induced arthritis Rapid onset of effect in fully established disease Reversal of fully established disease ED50 = 4.5 mg/kg/day
Slide 16: BTK is critically involved in Mast Cell Degranulation
BTK is critically involved in Mast Cell Degranulation an important contributor in Asthma and Allergy 100 90 80 70 60 AIgE induced HR AIgE induced IL-4 50 FMLP induced HR % Inhibition A23187 induced HR 40 A23187 induced IL-4 30 20 10 0 0.001 0.01 0.1 1 10 Mean ±SE Area of Extravasation PCI-32765 (µM)
Slide 17: Summary of BTK Oncology Program
Summary of BTK Oncology Program § Validation for safety and efficacy of a BTK inhibition exists with the human genetic disease (XLA) § Two distinct chemical development programs optimized from structure based design (32765 for oncology and 4-Series for autoimmune and allergy & asthma diseases) § Hig
Slide 18: BTK Inhibitors vs. Rituximab
BTK Inhibitors vs. Rituximab PCI-32765/PCI-4 Series Rituximab Target BTK CD20 Cellular selectivity Inhibition of B and mast Nonspecific B cell cell activation; genetic killing target in oncology in part identified to be ABC DLBCL phenotype Duration of effect 24 to 48 hours; no 24 -150 weeks; immunod
Slide 19: BTK has a wider expression than Rituxan (CD20)
BTK has a wider expression than Rituxan (CD20)
Slide 20: Emerging Recognition and Interest in this new Therapeutic Class
Emerging Recognition and Interest in this new Therapeutic Class ‘”PCYC’s BTK Inhibitors have the “The specificity of Pharmacyclic’s potential of becoming a very real BTK Inhibitors for B cells is really alternative to Rituxan® and have remarkable and unique. This drug great potential in autoimmune c
Slide 21: HDAC Inhibitor: PCI-24781
HDAC Inhibitor: PCI-24781 Currently entering Phase II trials Primary Indications • Solid Tumors • Hematological Malignancies § Potent oral inhibitor - 4-5 hour half-life to optimize the duration of acetylation § Pharmacodynamic assays used to assess drug exposure (acetylation) and response (Rad51) §
Slide 22: Phase I Safety Comparison
Phase I Safety Comparison PCI-24781 is class leading Grade III or greater reported Phase I toxicities (as of June 1, 2009) PCI-24781: 1 case of fatigue in 70 patients; thrombocytopenia (reversible, asymptomatic) LBH-589: Cardiac QT prolongation, nausea (40%), diarrhea (33%), vomiting (33%), hpokalem
Slide 23: Comparison of Phase I Responses
Comparison of Phase I Responses PCI-24781 versus the competition in Phase I Observed responses in ongoing clinical trials as of June 1, 2009 PCYC-0401 (solid tumors): 5/15 SD (33%) 38% PCYC-0402 (solid tumors): 4/19 SD (21%) combined PCYC-0403 (lymphomas): 6/11 SD and 2 PR (72%) response Two PR (Fol
Slide 24: PCYC has leading research in HDAC
PCYC has leading research in HDAC Dr. Edward A. Sausville, M.D. Ph.D., former Associate Director NCI and Professor of Medicine University of Maryland Greenebaum Cancer Center, Pharmacyclics’ Advisory Board Member “PCI-24781 is an important HDAC inhibitor which is differentiating itself by virtue of
Slide 25: Servier Partnership - HDAC
Servier Partnership - HDAC Ex-US Development § $10.45 Million Upfront Payment § $4 Million in Guaranteed Research Payments over 24 Months § ~$39 Million in Total Milestones § High single digit royalties in EU and Japan § Servier responsible for all clinical trials in ex-US with substantial clinical
Slide 26: Factor VIIa Inhibitor: PCI-27483
Factor VIIa Inhibitor: PCI-27483 Primary Indications • Tumors over expressing Tissue Factor (TF) • Pancreatic Cancer • Stomach/Colon • Lung • Breast • Melanoma § Structure-based drug design using crystallography, purified human FVIIa, and enzymatic assays § Molecule optimized for potency, selectivit
Slide 27: Factor VIIa Pathway's Dual Role
Factor VIIa Pathway’s Dual Role Oncogene Activation / Loss of Tumor Suppressor Genes Blood Vessel I = LMWH Thrombin I = PCI-27483 FX FXa FX FXa I FVII I X I FVII FVIIa FVIIa TF TF TF PAR2 PAR1 PAR2 SIGNALING via MAPK del p53 mut K-ras Extravascular Tumor Cell Growth factors VEGF, IL-8, cytokines Met
Slide 28: Validation Studies on Target
Validation Studies on Target Overexpression, Prevalence, VTE incidence Tissue factor expression is prevalent Venous Thromboembolism in Cancer in numerous tumor types by IHC is a Significant Clinical Event Cancer site Prevalence (%) All malignancies 10 - 15 - Pancreas 28 - Lung 27 - Stomach 13 - Brea
Slide 29: Strong preclinical activity in animal models
Strong preclinical activity in animal models BxPC3 Pancreatic Tumor Xenografts PCI-27483 and Gemcitabine Tumor Growth Inhibition: Mean ± SE Tumor Volume (mm 225 Vehicle BID ) PCI-27483 75 m g/kg BID 3 Gemcitabine 30*- 40** m g/kg PCI-27483 + Gemcitabine 16.7% with gemcitabine only 175 71.3% with PCI
Slide 30: Phase I Study with FVIIa Inhibitor PCI-27483
Phase I Study with FVIIa Inhibitor PCI-27483 Precise control of coagulation in Phase I Cohorts 2, 3 and 4 Mean INR ± SEM 3.00 Mean for Cohort at 0.2 mg/kg Mean for Cohort at 0.8 mg/kg § Phase I complete 2.50 Mean for Cohort at 2.0 mg/kg § Single subcutaneous doses: 2.00 0.05, 0.20, 0.80 and 2.0 mg/k
Slide 31: Patent Estate
Patent Estate Strong patent estate with: 148 patents issued or pending with global coverage in major markets BTK- 37 HDAC- 42 Factor VII 19 MGd- 50
Slide 32: Financial Overview Pre Rights Offering
Financial Overview Pre Rights Offering Snapshot: § Cash at the end of March 2009, including the Servier payment, approximately $22M § $4M of guaranteed R&D payment from Servier in the next 2 years, with an additional $24.5M upon the achievements of certain milestones § $24M expected proceeds from th
Slide 33: The Rights Offering
The Rights Offering § Equity raise of up to $24 Million in the Offering. Up to 18,750,000 newly issued shares. Each subscription right entitles record holders, as of July 15, 2009 to purchase 0.6808 shares at a price of $1.28 / share. § Example: A Record Holder owns 10,000 shares. Offering enables a
Slide 34: Fiscal 2009 vs 2010 Patient Enrollment
Fiscal 2009 vs 2010 Patient Enrollment Planned Enrollment of Patients Fiscal 2009 versus Fiscal 2010 Pharmacyclics plans to significantly increase the number of patients in clinical trials Q1 Act Q2 Act Q3 Act Q4 09 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 2010 Patients enrolled
Slide 35: Fiscal 2009 vs 2010 Fixed Expenses
Fiscal 2009 vs 2010 Fixed Expenses Fixed Expenses (admin, building, employee, accounting, legal etc.) Pharmacyclics plans to keep the fixed expenses about the same in 2010 Q1 Act Q2 Act Q3 Act Q4 09 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 2010 PCYC Fixed Expenses
Slide 36: Fiscal 2009 vs 2010 Fixed Expenses per Patient
Fiscal 2009 vs 2010 Fixed Expenses per Patient Average Fixed Expenses per Patient in Fiscal 2009 versus 2010 Pharmacyclics plans to significantly lower the fixed cost per patient Q1 Act Q2 Act Q3 Act Q4 09 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 2010 PCYC Fixed Expenses / per patient
Slide 37: Fiscal 2009 vs 2010 Program related Expenses
Fiscal 2009 vs 2010 Program related Expenses Pharmacyclics planned drug program spending Fiscal 2009 versus 2010 Q1 Act Q2 Act Q3 Act Q4 09 2009 Q1 2010 Q2 2010 Q3 2010 Q4 2010 2010 Faktor VII HDAC BTK 32765 BTK 4 Series
Slide 38: What we discover today creates a wave of change for a better tomorrow
What we discover today…… creates a wave of change for a better tomorrow